 Brian Freed
Concepts (523)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HLA-DRB1 Chains | 8 | 2025 | 109 | 1.670 |
Why?
| | T-Lymphocytes | 22 | 2025 | 1982 | 1.370 |
Why?
| | Epitopes | 4 | 2016 | 485 | 1.160 |
Why?
| | HLA Antigens | 9 | 2024 | 225 | 0.880 |
Why?
| | Genetic Predisposition to Disease | 6 | 2016 | 2365 | 0.850 |
Why?
| | Lymphocyte Activation | 19 | 2006 | 1126 | 0.830 |
Why?
| | Arthritis, Rheumatoid | 4 | 2025 | 1169 | 0.810 |
Why?
| | Interleukin-2 | 16 | 2005 | 437 | 0.740 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2021 | 1721 | 0.680 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 2022 | 124 | 0.680 |
Why?
| | Hydroquinones | 6 | 2003 | 29 | 0.670 |
Why?
| | Kidney Transplantation | 20 | 2019 | 704 | 0.660 |
Why?
| | Back Pain | 1 | 2021 | 52 | 0.640 |
Why?
| | HLA-B Antigens | 3 | 2024 | 57 | 0.620 |
Why?
| | HLA-DR Antigens | 5 | 2020 | 220 | 0.580 |
Why?
| | Alleles | 8 | 2025 | 881 | 0.550 |
Why?
| | Tars | 3 | 2006 | 5 | 0.540 |
Why?
| | Graft Rejection | 14 | 2019 | 540 | 0.540 |
Why?
| | Acrolein | 2 | 2007 | 22 | 0.490 |
Why?
| | Immunosuppressive Agents | 13 | 2017 | 847 | 0.480 |
Why?
| | Vimentin | 2 | 2016 | 54 | 0.460 |
Why?
| | Cyclosporins | 11 | 1991 | 71 | 0.460 |
Why?
| | Peptides, Cyclic | 2 | 2016 | 275 | 0.420 |
Why?
| | Catechols | 4 | 2003 | 15 | 0.410 |
Why?
| | Histocompatibility Antigens Class I | 3 | 2022 | 202 | 0.390 |
Why?
| | Peptides | 2 | 2016 | 998 | 0.390 |
Why?
| | Transplantation, Haploidentical | 2 | 2024 | 23 | 0.390 |
Why?
| | Tissue Donors | 6 | 2018 | 424 | 0.380 |
Why?
| | Histocompatibility Antigens Class II | 5 | 2022 | 364 | 0.370 |
Why?
| | Programmed Cell Death 1 Receptor | 3 | 2020 | 264 | 0.360 |
Why?
| | Smoking | 5 | 2011 | 1472 | 0.360 |
Why?
| | Fetal Blood | 6 | 2024 | 342 | 0.360 |
Why?
| | Cord Blood Stem Cell Transplantation | 5 | 2016 | 103 | 0.350 |
Why?
| | Immune Tolerance | 4 | 2025 | 379 | 0.350 |
Why?
| | DNA | 7 | 2007 | 1464 | 0.340 |
Why?
| | Smoke | 5 | 2007 | 148 | 0.340 |
Why?
| | B-Lymphocytes | 7 | 2021 | 877 | 0.340 |
Why?
| | Double-Blind Method | 2 | 2024 | 2029 | 0.330 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 5 | 2013 | 851 | 0.330 |
Why?
| | Humans | 93 | 2024 | 144957 | 0.320 |
Why?
| | Ribonucleotide Reductases | 2 | 2000 | 29 | 0.300 |
Why?
| | Graft Survival | 9 | 2017 | 526 | 0.300 |
Why?
| | Arachis | 1 | 2010 | 108 | 0.300 |
Why?
| | Immunoglobulin E | 1 | 2010 | 315 | 0.290 |
Why?
| | Immunoglobulin G | 4 | 2013 | 893 | 0.280 |
Why?
| | Peanut Hypersensitivity | 1 | 2010 | 143 | 0.280 |
Why?
| | Cells, Cultured | 11 | 2019 | 4155 | 0.270 |
Why?
| | Lymphocytes | 3 | 2013 | 382 | 0.260 |
Why?
| | NF-kappa B p50 Subunit | 1 | 2007 | 22 | 0.260 |
Why?
| | Isoantibodies | 3 | 2017 | 57 | 0.260 |
Why?
| | Disease Models, Animal | 5 | 2021 | 4569 | 0.250 |
Why?
| | Plants, Toxic | 3 | 2000 | 18 | 0.240 |
Why?
| | CD4-Positive T-Lymphocytes | 5 | 2016 | 1129 | 0.240 |
Why?
| | Cyclin-Dependent Kinase 4 | 1 | 2006 | 53 | 0.230 |
Why?
| | Cyclin-Dependent Kinase 6 | 1 | 2006 | 49 | 0.230 |
Why?
| | Immune System | 2 | 2021 | 179 | 0.230 |
Why?
| | Histocompatibility Testing | 7 | 2019 | 121 | 0.230 |
Why?
| | Flow Cytometry | 5 | 2016 | 1173 | 0.220 |
Why?
| | Tuberculosis | 2 | 2023 | 291 | 0.220 |
Why?
| | Enzyme Inhibitors | 2 | 2000 | 826 | 0.220 |
Why?
| | Ethylmaleimide | 3 | 1991 | 18 | 0.220 |
Why?
| | Mycobacterium tuberculosis | 2 | 2023 | 337 | 0.220 |
Why?
| | Hematopoietic Stem Cell Transplantation | 3 | 2024 | 676 | 0.220 |
Why?
| | Mental Disorders | 1 | 2014 | 1172 | 0.220 |
Why?
| | Antibodies | 3 | 2019 | 403 | 0.220 |
Why?
| | Haplotypes | 3 | 2014 | 490 | 0.210 |
Why?
| | Ganciclovir | 4 | 1997 | 53 | 0.210 |
Why?
| | Cell Line | 10 | 2016 | 2882 | 0.200 |
Why?
| | Cytomegalovirus Infections | 5 | 1997 | 206 | 0.200 |
Why?
| | Gene Frequency | 3 | 2019 | 481 | 0.200 |
Why?
| | Islets of Langerhans | 3 | 1994 | 833 | 0.190 |
Why?
| | Glutamic Acid | 1 | 2025 | 251 | 0.190 |
Why?
| | Diabetes Mellitus, Type 1 | 5 | 2014 | 3890 | 0.190 |
Why?
| | HLA-A Antigens | 1 | 2022 | 52 | 0.190 |
Why?
| | HLA-C Antigens | 1 | 2022 | 36 | 0.180 |
Why?
| | Collagen | 1 | 2025 | 456 | 0.180 |
Why?
| | Interferon-gamma | 3 | 2005 | 784 | 0.180 |
Why?
| | Cigarette Smoking | 1 | 2023 | 99 | 0.180 |
Why?
| | Tumor Necrosis Factor-alpha | 3 | 2005 | 1217 | 0.180 |
Why?
| | Histocompatibility Antigens | 1 | 2022 | 102 | 0.180 |
Why?
| | Cyclosporine | 5 | 1998 | 265 | 0.170 |
Why?
| | Protein Binding | 3 | 2016 | 2276 | 0.170 |
Why?
| | In Vitro Techniques | 9 | 2005 | 1048 | 0.170 |
Why?
| | Receptors, KIR | 2 | 2022 | 110 | 0.170 |
Why?
| | Enoxaparin | 1 | 2022 | 67 | 0.170 |
Why?
| | Central Tolerance | 1 | 2021 | 10 | 0.170 |
Why?
| | Precursor Cells, B-Lymphoid | 1 | 2021 | 41 | 0.170 |
Why?
| | DNA-Binding Proteins | 2 | 2011 | 1500 | 0.160 |
Why?
| | Transplantation, Homologous | 9 | 2019 | 415 | 0.160 |
Why?
| | Receptors, CXCR4 | 1 | 2021 | 91 | 0.160 |
Why?
| | HLA-DRB4 Chains | 1 | 2020 | 6 | 0.160 |
Why?
| | Heterografts | 1 | 2021 | 144 | 0.160 |
Why?
| | Gene Expression Regulation | 3 | 2016 | 2609 | 0.160 |
Why?
| | Receptors, Interleukin-2 | 5 | 2003 | 64 | 0.160 |
Why?
| | Mice | 18 | 2025 | 18365 | 0.160 |
Why?
| | Evolution, Molecular | 1 | 2024 | 515 | 0.160 |
Why?
| | Brain Ischemia | 1 | 2024 | 358 | 0.160 |
Why?
| | Cell Division | 4 | 1997 | 766 | 0.160 |
Why?
| | Nickel | 1 | 2020 | 64 | 0.160 |
Why?
| | Trace Elements | 1 | 2020 | 52 | 0.150 |
Why?
| | Antineoplastic Agents, Immunological | 2 | 2020 | 199 | 0.150 |
Why?
| | Bias | 1 | 2021 | 202 | 0.150 |
Why?
| | Receptors, Antigen, B-Cell | 2 | 2021 | 134 | 0.150 |
Why?
| | alpha 1-Antitrypsin | 1 | 2020 | 102 | 0.150 |
Why?
| | Transcription Factors | 2 | 2005 | 1742 | 0.150 |
Why?
| | Pulmonary Alveolar Proteinosis | 1 | 2019 | 16 | 0.150 |
Why?
| | Cell Cycle Proteins | 1 | 2003 | 629 | 0.150 |
Why?
| | Immunotherapy | 2 | 2021 | 657 | 0.150 |
Why?
| | Adrenal Cortex Neoplasms | 1 | 2020 | 65 | 0.140 |
Why?
| | Vascular System Injuries | 1 | 2019 | 77 | 0.140 |
Why?
| | Adrenocortical Carcinoma | 1 | 2020 | 67 | 0.140 |
Why?
| | Animals | 26 | 2025 | 38109 | 0.140 |
Why?
| | Unrelated Donors | 2 | 2024 | 38 | 0.140 |
Why?
| | Tacrolimus | 2 | 2017 | 196 | 0.140 |
Why?
| | Tumor Microenvironment | 2 | 2020 | 735 | 0.140 |
Why?
| | Insulin | 3 | 1994 | 2507 | 0.140 |
Why?
| | HEK293 Cells | 2 | 2022 | 744 | 0.140 |
Why?
| | Peripheral Blood Stem Cell Transplantation | 1 | 2018 | 35 | 0.140 |
Why?
| | Transcription, Genetic | 2 | 2003 | 1496 | 0.130 |
Why?
| | Herpesvirus 4, Human | 1 | 2018 | 176 | 0.130 |
Why?
| | Hydrogen Peroxide | 3 | 1988 | 336 | 0.130 |
Why?
| | Cell Transplantation | 1 | 1997 | 39 | 0.130 |
Why?
| | Donor Selection | 1 | 2018 | 79 | 0.130 |
Why?
| | Hypersensitivity | 1 | 2020 | 252 | 0.130 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2018 | 101 | 0.130 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2019 | 220 | 0.130 |
Why?
| | Antiviral Agents | 3 | 2020 | 768 | 0.130 |
Why?
| | Proinsulin | 1 | 1997 | 51 | 0.130 |
Why?
| | Mutagenesis, Site-Directed | 2 | 2016 | 381 | 0.130 |
Why?
| | Amino Acid Sequence | 4 | 2016 | 2157 | 0.120 |
Why?
| | Benzoquinones | 1 | 1997 | 47 | 0.120 |
Why?
| | Mice, Inbred BALB C | 5 | 2021 | 1253 | 0.120 |
Why?
| | Transplantation Conditioning | 1 | 2018 | 186 | 0.120 |
Why?
| | Carcinogenesis | 1 | 2018 | 229 | 0.120 |
Why?
| | Complement System Proteins | 1 | 2019 | 316 | 0.120 |
Why?
| | Interleukin-1 | 1 | 2000 | 961 | 0.120 |
Why?
| | Genetic Variation | 2 | 2015 | 984 | 0.120 |
Why?
| | Phosphopyruvate Hydratase | 1 | 2016 | 26 | 0.120 |
Why?
| | HLA-DQ beta-Chains | 1 | 2016 | 57 | 0.120 |
Why?
| | Dextrans | 1 | 2016 | 86 | 0.120 |
Why?
| | Collagen Type II | 1 | 2016 | 54 | 0.120 |
Why?
| | Autoantibodies | 4 | 2021 | 1504 | 0.120 |
Why?
| | Cytotoxicity, Immunologic | 3 | 2012 | 223 | 0.120 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 1 | 2018 | 192 | 0.120 |
Why?
| | Triple Negative Breast Neoplasms | 1 | 2019 | 216 | 0.120 |
Why?
| | Female | 29 | 2024 | 78376 | 0.120 |
Why?
| | Genotype | 3 | 2022 | 1835 | 0.110 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2022 | 1141 | 0.110 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2016 | 396 | 0.110 |
Why?
| | Adult | 19 | 2024 | 40506 | 0.110 |
Why?
| | Resting Phase, Cell Cycle | 2 | 2006 | 16 | 0.110 |
Why?
| | Genetic Therapy | 1 | 1997 | 313 | 0.110 |
Why?
| | Protein Kinase C | 1 | 1996 | 252 | 0.110 |
Why?
| | Retrospective Studies | 10 | 2024 | 17101 | 0.110 |
Why?
| | Tobacco Smoke Pollution | 1 | 1997 | 233 | 0.110 |
Why?
| | Methylprednisolone | 3 | 1991 | 64 | 0.110 |
Why?
| | Stroke | 1 | 2024 | 1258 | 0.110 |
Why?
| | Autoimmune Diseases | 1 | 2019 | 463 | 0.110 |
Why?
| | G1 Phase | 2 | 2006 | 66 | 0.110 |
Why?
| | Clonal Anergy | 1 | 1994 | 54 | 0.110 |
Why?
| | Kidney Failure, Chronic | 2 | 2017 | 598 | 0.110 |
Why?
| | Autoimmunity | 2 | 2021 | 927 | 0.100 |
Why?
| | Immunoglobulin Isotypes | 1 | 2013 | 35 | 0.100 |
Why?
| | Tumor Cells, Cultured | 4 | 2020 | 919 | 0.100 |
Why?
| | Lymphocyte Culture Test, Mixed | 7 | 1996 | 51 | 0.100 |
Why?
| | Sequence Analysis, RNA | 1 | 2016 | 442 | 0.100 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2020 | 988 | 0.100 |
Why?
| | Endothelial Cells | 1 | 2019 | 870 | 0.100 |
Why?
| | Hypoxanthine Phosphoribosyltransferase | 1 | 2013 | 24 | 0.100 |
Why?
| | Cell Cycle | 3 | 2006 | 597 | 0.100 |
Why?
| | C-Reactive Protein | 2 | 1987 | 417 | 0.100 |
Why?
| | Radioimmunoassay | 5 | 1990 | 165 | 0.100 |
Why?
| | Models, Biological | 1 | 2020 | 1822 | 0.100 |
Why?
| | Models, Animal | 2 | 2013 | 392 | 0.090 |
Why?
| | Male | 23 | 2024 | 72406 | 0.090 |
Why?
| | Dried Blood Spot Testing | 1 | 2013 | 126 | 0.090 |
Why?
| | Transduction, Genetic | 1 | 2013 | 133 | 0.090 |
Why?
| | Complementarity Determining Regions | 1 | 2012 | 53 | 0.090 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2021 | 930 | 0.090 |
Why?
| | Leukemia L1210 | 1 | 1992 | 7 | 0.090 |
Why?
| | Pulmonary Fibrosis | 1 | 2016 | 395 | 0.090 |
Why?
| | Indoles | 1 | 1996 | 501 | 0.090 |
Why?
| | Islets of Langerhans Transplantation | 1 | 1992 | 67 | 0.090 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 2 | 2012 | 331 | 0.090 |
Why?
| | Gene Knockdown Techniques | 1 | 2013 | 336 | 0.090 |
Why?
| | Chagas Disease | 1 | 2012 | 42 | 0.090 |
Why?
| | Middle Aged | 13 | 2024 | 35928 | 0.090 |
Why?
| | Beryllium | 2 | 2005 | 161 | 0.090 |
Why?
| | Bronchiolitis Obliterans | 1 | 2012 | 66 | 0.090 |
Why?
| | Mice, Transgenic | 3 | 2025 | 2185 | 0.090 |
Why?
| | Blood Specimen Collection | 1 | 2011 | 38 | 0.090 |
Why?
| | Lung | 4 | 2007 | 4109 | 0.090 |
Why?
| | Interleukin Receptor Common gamma Subunit | 1 | 2011 | 14 | 0.090 |
Why?
| | Blood Banks | 1 | 2011 | 50 | 0.090 |
Why?
| | Calcium | 2 | 1994 | 1184 | 0.080 |
Why?
| | Transplantation Chimera | 1 | 2011 | 56 | 0.080 |
Why?
| | Maleimides | 1 | 1991 | 21 | 0.080 |
Why?
| | Postoperative Complications | 5 | 2017 | 2920 | 0.080 |
Why?
| | International Cooperation | 1 | 2011 | 198 | 0.080 |
Why?
| | Child, Preschool | 6 | 2014 | 11799 | 0.080 |
Why?
| | Chromatography, High Pressure Liquid | 7 | 2005 | 598 | 0.080 |
Why?
| | Receptors, Transferrin | 2 | 2003 | 28 | 0.080 |
Why?
| | Mice, Knockout | 5 | 2021 | 3125 | 0.080 |
Why?
| | Colorectal Neoplasms | 1 | 2019 | 848 | 0.080 |
Why?
| | Spleen | 1 | 2013 | 508 | 0.080 |
Why?
| | Fibroblasts | 2 | 1994 | 1034 | 0.080 |
Why?
| | Serine Endopeptidases | 2 | 2022 | 128 | 0.080 |
Why?
| | Skin Tests | 1 | 2010 | 94 | 0.080 |
Why?
| | Mitogens | 2 | 1988 | 55 | 0.080 |
Why?
| | Lymph Nodes | 1 | 2013 | 502 | 0.080 |
Why?
| | Antibody Formation | 1 | 1991 | 294 | 0.080 |
Why?
| | Algorithms | 1 | 2018 | 1839 | 0.080 |
Why?
| | Siblings | 1 | 2010 | 195 | 0.080 |
Why?
| | Hematopoietic Stem Cells | 1 | 2013 | 420 | 0.080 |
Why?
| | Jurkat Cells | 2 | 2000 | 114 | 0.080 |
Why?
| | Cesarean Section | 1 | 2011 | 224 | 0.070 |
Why?
| | Genes, T-Cell Receptor beta | 2 | 2007 | 23 | 0.070 |
Why?
| | Base Sequence | 3 | 2012 | 2191 | 0.070 |
Why?
| | Genome-Wide Association Study | 1 | 2016 | 1407 | 0.070 |
Why?
| | Nicotine | 2 | 2023 | 332 | 0.070 |
Why?
| | Disease Susceptibility | 1 | 2011 | 348 | 0.070 |
Why?
| | HLA-DQ Antigens | 2 | 2000 | 173 | 0.070 |
Why?
| | Immunoglobulins, Intravenous | 3 | 1995 | 126 | 0.070 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 1958 | 0.070 |
Why?
| | Survival Rate | 5 | 2017 | 2092 | 0.070 |
Why?
| | Cricetinae | 3 | 1994 | 304 | 0.070 |
Why?
| | Cell Survival | 3 | 1997 | 1098 | 0.070 |
Why?
| | Idiopathic Pulmonary Fibrosis | 1 | 2016 | 691 | 0.070 |
Why?
| | Lung Transplantation | 1 | 2012 | 338 | 0.070 |
Why?
| | Phytohemagglutinins | 4 | 1991 | 29 | 0.070 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 2 | 2020 | 154 | 0.070 |
Why?
| | Allografts | 2 | 2019 | 150 | 0.070 |
Why?
| | Adolescent | 7 | 2014 | 22453 | 0.070 |
Why?
| | Research Design | 1 | 2014 | 1137 | 0.070 |
Why?
| | Anemia, Sickle Cell | 1 | 2012 | 312 | 0.070 |
Why?
| | Amino Acids | 1 | 2011 | 522 | 0.070 |
Why?
| | Molecular Sequence Data | 3 | 2012 | 2931 | 0.070 |
Why?
| | Genetic Linkage | 2 | 2006 | 273 | 0.070 |
Why?
| | Mice, Nude | 2 | 2020 | 688 | 0.070 |
Why?
| | Mice, Inbred NOD | 2 | 2021 | 610 | 0.060 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2019 | 917 | 0.060 |
Why?
| | Isoantigens | 1 | 1987 | 17 | 0.060 |
Why?
| | Cell Differentiation | 4 | 2021 | 2050 | 0.060 |
Why?
| | Transcription Factor AP-1 | 1 | 2007 | 79 | 0.060 |
Why?
| | NFATC Transcription Factors | 1 | 2007 | 93 | 0.060 |
Why?
| | Cloning, Molecular | 2 | 1998 | 541 | 0.060 |
Why?
| | Kidney Function Tests | 2 | 2017 | 157 | 0.060 |
Why?
| | Aged | 6 | 2024 | 25947 | 0.060 |
Why?
| | Follow-Up Studies | 5 | 2018 | 5417 | 0.060 |
Why?
| | Aldehydes | 1 | 2007 | 142 | 0.060 |
Why?
| | HLA-B15 Antigen | 1 | 2006 | 12 | 0.060 |
Why?
| | Enzyme Induction | 1 | 2006 | 88 | 0.060 |
Why?
| | Muromonab-CD3 | 2 | 1997 | 6 | 0.060 |
Why?
| | Sequence Homology | 1 | 2006 | 43 | 0.060 |
Why?
| | Lung Diseases | 2 | 2006 | 787 | 0.060 |
Why?
| | Butylated Hydroxytoluene | 1 | 2006 | 36 | 0.060 |
Why?
| | Bone Marrow | 2 | 2021 | 306 | 0.060 |
Why?
| | Prognosis | 4 | 2017 | 4293 | 0.060 |
Why?
| | Microspheres | 1 | 2006 | 142 | 0.060 |
Why?
| | HLA-DP Antigens | 1 | 2005 | 32 | 0.060 |
Why?
| | Cysteine | 1 | 2007 | 210 | 0.060 |
Why?
| | Phenotype | 3 | 2021 | 3164 | 0.060 |
Why?
| | Autoantigens | 2 | 2021 | 429 | 0.060 |
Why?
| | Phospholipases A | 1 | 2006 | 98 | 0.060 |
Why?
| | Arginine | 1 | 2007 | 262 | 0.060 |
Why?
| | Cell Proliferation | 2 | 2020 | 2499 | 0.060 |
Why?
| | Biliary Atresia | 1 | 2007 | 158 | 0.060 |
Why?
| | Neoplasms | 1 | 2021 | 2884 | 0.060 |
Why?
| | Transfection | 2 | 1998 | 940 | 0.060 |
Why?
| | Phenols | 1 | 2006 | 114 | 0.060 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2005 | 131 | 0.060 |
Why?
| | Child | 5 | 2014 | 22657 | 0.060 |
Why?
| | NAD(P)H Dehydrogenase (Quinone) | 1 | 2004 | 34 | 0.050 |
Why?
| | Arteriosclerosis | 1 | 2005 | 84 | 0.050 |
Why?
| | Chemokines, CXC | 1 | 2004 | 68 | 0.050 |
Why?
| | Treatment Outcome | 5 | 2024 | 11695 | 0.050 |
Why?
| | Acetylcysteine | 1 | 2005 | 139 | 0.050 |
Why?
| | Antigen Presentation | 1 | 2005 | 205 | 0.050 |
Why?
| | Skin Transplantation | 1 | 2025 | 85 | 0.050 |
Why?
| | Structure-Activity Relationship | 3 | 1991 | 570 | 0.050 |
Why?
| | Amino Acid Substitution | 1 | 2025 | 304 | 0.050 |
Why?
| | Reoperation | 3 | 1998 | 631 | 0.050 |
Why?
| | Case-Control Studies | 1 | 2011 | 3608 | 0.050 |
Why?
| | Agglutination | 2 | 1997 | 5 | 0.050 |
Why?
| | Young Adult | 3 | 2024 | 14126 | 0.050 |
Why?
| | Bone Marrow Transplantation | 1 | 2025 | 294 | 0.050 |
Why?
| | Pandemics | 2 | 2024 | 1695 | 0.050 |
Why?
| | Surveys and Questionnaires | 1 | 2016 | 6053 | 0.050 |
Why?
| | Antigens, Differentiation, B-Lymphocyte | 1 | 2003 | 37 | 0.050 |
Why?
| | Concanavalin A | 3 | 1988 | 71 | 0.050 |
Why?
| | Berylliosis | 1 | 2005 | 202 | 0.050 |
Why?
| | E2F Transcription Factors | 1 | 2003 | 62 | 0.050 |
Why?
| | Lectins, C-Type | 1 | 2003 | 62 | 0.050 |
Why?
| | Antigens, Differentiation, T-Lymphocyte | 1 | 2003 | 100 | 0.050 |
Why?
| | Glomerular Filtration Rate | 2 | 2017 | 760 | 0.050 |
Why?
| | Polymorphism, Genetic | 1 | 2006 | 612 | 0.050 |
Why?
| | Mesocricetus | 2 | 1992 | 46 | 0.050 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2004 | 381 | 0.050 |
Why?
| | Immunophenotyping | 2 | 2015 | 322 | 0.050 |
Why?
| | Risk Factors | 6 | 2017 | 10792 | 0.050 |
Why?
| | Superoxide Dismutase | 1 | 2004 | 301 | 0.050 |
Why?
| | Cell Line, Transformed | 2 | 1992 | 140 | 0.050 |
Why?
| | Respiratory Tract Infections | 1 | 2007 | 398 | 0.050 |
Why?
| | Phosphoproteins | 1 | 2005 | 346 | 0.050 |
Why?
| | Severity of Illness Index | 1 | 2010 | 2925 | 0.050 |
Why?
| | Biomarkers | 2 | 2019 | 4275 | 0.050 |
Why?
| | Drug Synergism | 2 | 1996 | 357 | 0.040 |
Why?
| | Reactive Oxygen Species | 1 | 2005 | 621 | 0.040 |
Why?
| | Cell Communication | 2 | 2013 | 324 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2003 | 167 | 0.040 |
Why?
| | T-Lymphocytes, Cytotoxic | 3 | 1987 | 177 | 0.040 |
Why?
| | Cyclophosphamide | 1 | 2022 | 266 | 0.040 |
Why?
| | T-Lymphocyte Subsets | 2 | 2016 | 415 | 0.040 |
Why?
| | Neutrophils | 2 | 2005 | 1134 | 0.040 |
Why?
| | Apoptosis | 2 | 2020 | 2430 | 0.040 |
Why?
| | Leukemia | 2 | 2012 | 245 | 0.040 |
Why?
| | Antioxidants | 2 | 2006 | 549 | 0.040 |
Why?
| | Chimerism | 1 | 2021 | 35 | 0.040 |
Why?
| | Iron Chelating Agents | 1 | 2000 | 18 | 0.040 |
Why?
| | Biopsy | 2 | 2019 | 1077 | 0.040 |
Why?
| | Lymphocyte Subsets | 1 | 2021 | 83 | 0.040 |
Why?
| | Cell Separation | 2 | 2011 | 307 | 0.040 |
Why?
| | Antibody Specificity | 1 | 2001 | 181 | 0.040 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2023 | 389 | 0.040 |
Why?
| | Ganglionic Stimulants | 1 | 2000 | 15 | 0.040 |
Why?
| | Kidney | 4 | 2019 | 1496 | 0.040 |
Why?
| | Lymphoid Tissue | 1 | 2021 | 80 | 0.040 |
Why?
| | Virus Internalization | 1 | 2020 | 65 | 0.040 |
Why?
| | Leukocyte Elastase | 1 | 2020 | 75 | 0.040 |
Why?
| | Free Radicals | 1 | 2000 | 110 | 0.040 |
Why?
| | Dimerization | 1 | 2000 | 194 | 0.040 |
Why?
| | Blotting, Western | 2 | 2004 | 1187 | 0.040 |
Why?
| | RNA | 2 | 1997 | 940 | 0.040 |
Why?
| | Gene Expression | 1 | 2005 | 1490 | 0.040 |
Why?
| | Extracellular Traps | 1 | 2020 | 57 | 0.040 |
Why?
| | Antithrombins | 1 | 2020 | 70 | 0.040 |
Why?
| | Mice, SCID | 1 | 2021 | 369 | 0.040 |
Why?
| | Biological Evolution | 1 | 2024 | 488 | 0.040 |
Why?
| | Ligands | 1 | 2022 | 674 | 0.040 |
Why?
| | Tyrosine | 1 | 2000 | 222 | 0.040 |
Why?
| | Antigens, CD | 1 | 2003 | 555 | 0.040 |
Why?
| | Nephelometry and Turbidimetry | 2 | 2013 | 15 | 0.040 |
Why?
| | Arthroplasty, Replacement | 1 | 2020 | 47 | 0.040 |
Why?
| | Bone Marrow Cells | 1 | 2021 | 320 | 0.040 |
Why?
| | Luminescent Measurements | 2 | 2013 | 76 | 0.040 |
Why?
| | Inflammation | 3 | 2006 | 2880 | 0.040 |
Why?
| | Granuloma, Respiratory Tract | 1 | 1999 | 13 | 0.040 |
Why?
| | Receptors, Cytokine | 1 | 1999 | 36 | 0.040 |
Why?
| | Cytokines | 1 | 2007 | 2065 | 0.040 |
Why?
| | Xenobiotics | 1 | 1999 | 32 | 0.040 |
Why?
| | Steroid 21-Hydroxylase | 1 | 1999 | 27 | 0.040 |
Why?
| | Receptors, Interferon | 1 | 1999 | 60 | 0.040 |
Why?
| | Addison Disease | 1 | 1999 | 38 | 0.040 |
Why?
| | Viral Tropism | 1 | 2018 | 36 | 0.040 |
Why?
| | Antigens, CD34 | 2 | 2013 | 88 | 0.030 |
Why?
| | Metallothionein | 1 | 1998 | 25 | 0.030 |
Why?
| | Immunoglobulin M | 2 | 1991 | 284 | 0.030 |
Why?
| | Antibodies, Monoclonal | 3 | 1991 | 1524 | 0.030 |
Why?
| | Virus Latency | 1 | 2018 | 90 | 0.030 |
Why?
| | Virus Activation | 1 | 2018 | 95 | 0.030 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2019 | 161 | 0.030 |
Why?
| | Genotyping Techniques | 1 | 2018 | 69 | 0.030 |
Why?
| | Leukocytes, Mononuclear | 2 | 2012 | 573 | 0.030 |
Why?
| | Pokeweed Mitogens | 2 | 1988 | 7 | 0.030 |
Why?
| | Depression, Chemical | 1 | 1997 | 16 | 0.030 |
Why?
| | Mycophenolic Acid | 1 | 1998 | 120 | 0.030 |
Why?
| | Drug Therapy, Combination | 2 | 1998 | 1048 | 0.030 |
Why?
| | Acute Lung Injury | 1 | 2020 | 303 | 0.030 |
Why?
| | Lymphocyte Function-Associated Antigen-1 | 1 | 1997 | 27 | 0.030 |
Why?
| | 3T3 Cells | 1 | 1997 | 156 | 0.030 |
Why?
| | RNA, Messenger | 1 | 2005 | 2832 | 0.030 |
Why?
| | Insulin, Long-Acting | 1 | 1997 | 65 | 0.030 |
Why?
| | Anti-Inflammatory Agents | 1 | 2020 | 475 | 0.030 |
Why?
| | New York | 1 | 1997 | 127 | 0.030 |
Why?
| | Sulfhydryl Compounds | 2 | 1991 | 189 | 0.030 |
Why?
| | Guanidines | 1 | 1996 | 41 | 0.030 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 1997 | 138 | 0.030 |
Why?
| | Contraindications | 1 | 2016 | 91 | 0.030 |
Why?
| | Complement Activation | 1 | 2019 | 411 | 0.030 |
Why?
| | S Phase | 1 | 1996 | 80 | 0.030 |
Why?
| | Chromosomes, Human, Pair 6 | 1 | 2016 | 46 | 0.030 |
Why?
| | Immunoglobulin lambda-Chains | 1 | 2015 | 9 | 0.030 |
Why?
| | Costs and Cost Analysis | 1 | 1997 | 220 | 0.030 |
Why?
| | Half-Life | 2 | 1996 | 151 | 0.030 |
Why?
| | Immunoglobulin kappa-Chains | 1 | 2015 | 23 | 0.030 |
Why?
| | Infant, Newborn | 2 | 2021 | 6434 | 0.030 |
Why?
| | Linkage Disequilibrium | 1 | 2016 | 247 | 0.030 |
Why?
| | Liver | 3 | 2007 | 1888 | 0.030 |
Why?
| | Desensitization, Immunologic | 1 | 2016 | 89 | 0.030 |
Why?
| | B-Lymphocyte Subsets | 1 | 2015 | 80 | 0.030 |
Why?
| | Cross Reactions | 3 | 1990 | 130 | 0.030 |
Why?
| | Antigens, Viral, Tumor | 1 | 1994 | 7 | 0.030 |
Why?
| | Antigens, CD19 | 1 | 2015 | 129 | 0.030 |
Why?
| | Genetic Loci | 1 | 2016 | 261 | 0.030 |
Why?
| | Tetradecanoylphorbol Acetate | 1 | 1994 | 153 | 0.030 |
Why?
| | Iron | 1 | 1997 | 359 | 0.030 |
Why?
| | Transplant Recipients | 1 | 2016 | 180 | 0.030 |
Why?
| | Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 2 | 2007 | 27 | 0.030 |
Why?
| | Oxidative Stress | 1 | 2001 | 1339 | 0.030 |
Why?
| | Prevalence | 1 | 2001 | 2836 | 0.030 |
Why?
| | Mortality | 1 | 2016 | 376 | 0.030 |
Why?
| | Mice, Inbred DBA | 2 | 1992 | 187 | 0.030 |
Why?
| | Thioguanine | 1 | 2013 | 18 | 0.020 |
Why?
| | Cell Adhesion | 1 | 1994 | 455 | 0.020 |
Why?
| | Immunization, Passive | 1 | 1993 | 87 | 0.020 |
Why?
| | Lymphocyte Count | 1 | 2013 | 164 | 0.020 |
Why?
| | Umbilical Cord | 1 | 2013 | 91 | 0.020 |
Why?
| | Lymphocyte Depletion | 1 | 2013 | 132 | 0.020 |
Why?
| | Survivors | 1 | 2016 | 520 | 0.020 |
Why?
| | Adoptive Transfer | 1 | 2013 | 198 | 0.020 |
Why?
| | Drug Resistance | 1 | 2013 | 153 | 0.020 |
Why?
| | Survival Analysis | 2 | 2012 | 1385 | 0.020 |
Why?
| | Myeloid Cells | 1 | 2013 | 148 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2024 | 8279 | 0.020 |
Why?
| | Mercaptopurine | 1 | 1991 | 15 | 0.020 |
Why?
| | Seroepidemiologic Studies | 1 | 2012 | 172 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2019 | 2147 | 0.020 |
Why?
| | Mice, Inbred C57BL | 3 | 2011 | 5997 | 0.020 |
Why?
| | Anticoagulants | 1 | 2016 | 724 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2019 | 3550 | 0.020 |
Why?
| | Lymphoma | 1 | 2012 | 233 | 0.020 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 2006 | 636 | 0.020 |
Why?
| | Signal Transduction | 2 | 2021 | 5233 | 0.020 |
Why?
| | Blood Donors | 1 | 2011 | 143 | 0.020 |
Why?
| | Glucose | 1 | 1994 | 1049 | 0.020 |
Why?
| | Methylmannosides | 1 | 1989 | 1 | 0.020 |
Why?
| | Cytochalasins | 1 | 1989 | 3 | 0.020 |
Why?
| | Rosette Formation | 1 | 1989 | 14 | 0.020 |
Why?
| | Colchicine | 1 | 1989 | 21 | 0.020 |
Why?
| | Preoperative Care | 1 | 2012 | 380 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2016 | 1786 | 0.020 |
Why?
| | Fetus | 1 | 2013 | 803 | 0.020 |
Why?
| | Monocytes | 2 | 1989 | 538 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2013 | 1990 | 0.020 |
Why?
| | Animals, Newborn | 1 | 2011 | 902 | 0.020 |
Why?
| | Immunotherapy, Adoptive | 1 | 1992 | 337 | 0.020 |
Why?
| | Bile Ducts, Extrahepatic | 1 | 2007 | 20 | 0.020 |
Why?
| | Lipid Peroxides | 1 | 1987 | 10 | 0.020 |
Why?
| | Oligoclonal Bands | 1 | 2007 | 26 | 0.020 |
Why?
| | Interleukin-6 | 1 | 1991 | 780 | 0.020 |
Why?
| | Blood Glucose | 1 | 1997 | 2330 | 0.020 |
Why?
| | DNA Replication | 1 | 1989 | 251 | 0.020 |
Why?
| | Evaluation Studies as Topic | 1 | 1987 | 166 | 0.020 |
Why?
| | Cytotoxicity Tests, Immunologic | 1 | 2006 | 37 | 0.020 |
Why?
| | Chemokine CCL8 | 1 | 2006 | 3 | 0.020 |
Why?
| | Monocyte Chemoattractant Proteins | 1 | 2006 | 7 | 0.010 |
Why?
| | Predictive Value of Tests | 1 | 2012 | 2118 | 0.010 |
Why?
| | Phospholipases A2 | 1 | 2006 | 79 | 0.010 |
Why?
| | Chemokine CCL2 | 1 | 2006 | 116 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2013 | 3415 | 0.010 |
Why?
| | DNA, Complementary | 1 | 2005 | 277 | 0.010 |
Why?
| | Age Factors | 1 | 2013 | 3335 | 0.010 |
Why?
| | NADPH Dehydrogenase | 1 | 2005 | 6 | 0.010 |
Why?
| | Cytosol | 1 | 2006 | 227 | 0.010 |
Why?
| | NADH Dehydrogenase | 1 | 2005 | 20 | 0.010 |
Why?
| | Immunity, Cellular | 1 | 1987 | 272 | 0.010 |
Why?
| | Monitoring, Physiologic | 1 | 1987 | 289 | 0.010 |
Why?
| | Chemokine CXCL1 | 1 | 2004 | 76 | 0.010 |
Why?
| | Infant | 3 | 2007 | 10039 | 0.010 |
Why?
| | NADPH Oxidases | 1 | 2005 | 124 | 0.010 |
Why?
| | Translocation, Genetic | 1 | 2005 | 118 | 0.010 |
Why?
| | Leukemia, Lymphoid | 1 | 1983 | 27 | 0.010 |
Why?
| | Mice, Inbred AKR | 1 | 1983 | 37 | 0.010 |
Why?
| | Oxidation-Reduction | 1 | 1988 | 1087 | 0.010 |
Why?
| | Leukemia, Experimental | 1 | 1983 | 27 | 0.010 |
Why?
| | Lymphokines | 1 | 1983 | 130 | 0.010 |
Why?
| | Blood Transfusion | 1 | 1987 | 405 | 0.010 |
Why?
| | Enzyme Activation | 1 | 2004 | 768 | 0.010 |
Why?
| | Acute Disease | 1 | 2006 | 1031 | 0.010 |
Why?
| | Necrosis | 1 | 1984 | 244 | 0.010 |
Why?
| | Kinetics | 1 | 1986 | 1629 | 0.010 |
Why?
| | Rats | 3 | 2004 | 5614 | 0.010 |
Why?
| | Diagnosis, Differential | 1 | 2006 | 1495 | 0.010 |
Why?
| | Leukocyte Count | 1 | 2002 | 316 | 0.010 |
Why?
| | Cohort Studies | 1 | 2012 | 5965 | 0.010 |
Why?
| | HLA-DQ alpha-Chains | 1 | 2000 | 16 | 0.010 |
Why?
| | Anti-Bacterial Agents | 1 | 1991 | 1915 | 0.010 |
Why?
| | Genes, T-Cell Receptor alpha | 1 | 1999 | 11 | 0.010 |
Why?
| | Hematologic Neoplasms | 1 | 2002 | 162 | 0.010 |
Why?
| | Gene Rearrangement, alpha-Chain T-Cell Antigen Receptor | 1 | 1999 | 21 | 0.010 |
Why?
| | Cell Culture Techniques | 1 | 2002 | 375 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2004 | 2540 | 0.010 |
Why?
| | Clone Cells | 1 | 1999 | 266 | 0.010 |
Why?
| | United States | 1 | 2016 | 15988 | 0.010 |
Why?
| | Prospective Studies | 3 | 1996 | 7997 | 0.010 |
Why?
| | Pregnancy | 1 | 2011 | 7191 | 0.010 |
Why?
| | Azathioprine | 1 | 1998 | 49 | 0.010 |
Why?
| | Incidence | 2 | 1995 | 2883 | 0.010 |
Why?
| | Feasibility Studies | 1 | 2002 | 1095 | 0.010 |
Why?
| | Prednisone | 1 | 1998 | 221 | 0.010 |
Why?
| | Infusions, Intra-Arterial | 1 | 1996 | 61 | 0.010 |
Why?
| | Metabolic Clearance Rate | 1 | 1996 | 115 | 0.010 |
Why?
| | Risk Assessment | 1 | 2006 | 3676 | 0.010 |
Why?
| | Injections, Intravenous | 1 | 1996 | 200 | 0.010 |
Why?
| | Risk | 1 | 1999 | 911 | 0.010 |
Why?
| | Transplantation, Autologous | 1 | 1996 | 292 | 0.010 |
Why?
| | Blood Group Incompatibility | 1 | 1995 | 20 | 0.010 |
Why?
| | Dogs | 1 | 1996 | 438 | 0.010 |
Why?
| | Species Specificity | 2 | 1988 | 574 | 0.010 |
Why?
| | Cytomegalovirus | 1 | 1995 | 168 | 0.010 |
Why?
| | ABO Blood-Group System | 1 | 1995 | 57 | 0.010 |
Why?
| | Diabetic Nephropathies | 1 | 1998 | 318 | 0.010 |
Why?
| | Cadaver | 1 | 1995 | 304 | 0.010 |
Why?
| | Infusions, Intravenous | 1 | 1994 | 423 | 0.010 |
Why?
| | Drug Costs | 1 | 1994 | 116 | 0.010 |
Why?
| | Antibodies, Viral | 1 | 1995 | 672 | 0.010 |
Why?
| | Breast Neoplasms | 1 | 2002 | 2456 | 0.000 |
Why?
| | Rats, Inbred SHR | 1 | 1988 | 37 | 0.000 |
Why?
| | Deferoxamine | 1 | 1988 | 27 | 0.000 |
Why?
| | Malondialdehyde | 1 | 1988 | 30 | 0.000 |
Why?
| | Biotransformation | 1 | 1988 | 63 | 0.000 |
Why?
| | Length of Stay | 1 | 1994 | 1337 | 0.000 |
Why?
| | Injections, Subcutaneous | 1 | 1988 | 164 | 0.000 |
Why?
| | Tissue Distribution | 1 | 1988 | 334 | 0.000 |
Why?
| | Kidney Cortex | 1 | 1986 | 27 | 0.000 |
Why?
| | Kidney Medulla | 1 | 1986 | 31 | 0.000 |
Why?
| | Administration, Oral | 1 | 1988 | 848 | 0.000 |
Why?
| | Blood Physiological Phenomena | 1 | 1983 | 12 | 0.000 |
Why?
| | Suppressor Factors, Immunologic | 1 | 1983 | 4 | 0.000 |
Why?
| | Mice, Inbred CBA | 1 | 1983 | 57 | 0.000 |
Why?
| | Thymidine | 1 | 1983 | 60 | 0.000 |
Why?
| | Kidney Diseases | 1 | 1988 | 427 | 0.000 |
Why?
| | Rats, Inbred Strains | 1 | 1983 | 321 | 0.000 |
Why?
|
|
Freed's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|